BioStock published an article on 16 August 2021 about Cyxone, which can be read in full below. Swedish biotech Cyxone announced last month that the patient recruitment for its phase II trial testing Rabeximod in Covid-19 could come to...
Read MoreBioStock published an article on 15 July 2021 about Cyxone, which can be read in full below. After identifying new therapeutic treatment possibilities for T20K, Cyxone has announced a research collaboration with the Medical University of Vienna to further...
Read MoreBioStock published an article on 14 June 2021 about Cyxone, which can be read in full below. During May, Swedish biotech company Cyxone released a string of news. Recently, the company announced the recruitment of Carl-Magnus Högerkorp as new...
Read MoreBioStock published an article on 28 May 2021 about Cyxone, which can be read in full below. World MS Day will be celebrated on Sunday May 30th. It is a day to raise awareness of the condition, and to...
Read MoreBioStock published an article on 20 May 2021 about Cyxone, which can be read in full below. Recently, Malmö-based company Cyxone, announced the next development steps for its drug candidate T20K for the treatment of multiple sclerosis. A process...
Read MoreBioStock published an article on 18 May 2021 about Cyxone, which can be read in full below. Biotech company Cyxone is in the process of preparing drug candidate Rabeximod for the next clinical stage. Recently, the company announced a...
Read MoreRead the article with CEO Tara Heitner and COO Malin Berthold telling the story how Cyxone initiated the Covid-19 trial. Read the article here.
Read MoreBioStock published an article on 24 February 2021 about Cyxone, which can be read in full below. Biotech company Cyxone recently published its fourth quarter result, a period with great focus in the advancement of the project with the...
Read MoreBioStock published an article on 22 January 2021 about Cyxone, which can be read in full below. Last week, the biotech company Cyxone announced that the first patient has been screened in the phase II trial with their candidate...
Read MoreBioStock published an article on 14 December 2020 about Cyxone, which can be read in full below. Activity is high in Cyxone. The biotechnology company recently received approval to start a phase II study in Poland with Rabeximod in...
Read More